Core Viewpoint - Baosai Technology-B (02315) has seen a stock price increase of over 5%, currently trading at 55.75 HKD, with a transaction volume of 6.6351 million HKD [1] Financial Performance - For the fiscal year 2025, the company expects a revenue of approximately 1.379 billion RMB, representing a year-on-year growth of 40.63% [1] - The net profit attributable to the owners of the company is projected to be 173 million RMB, showing a significant year-on-year increase of 416.37% [1] - The net profit attributable to the owners of the company, excluding non-recurring gains and losses, is expected to be 116 million RMB, reflecting a year-on-year growth of 405.39% [1] - Total assets of the company are estimated to be 3.724 billion RMB, an increase of 54.20% compared to the beginning of the period [1] - Equity attributable to the owners of the company is projected to be 2.175 billion RMB, which is a substantial increase of 160.76% from the beginning of the period [1] Growth Drivers - The growth in operating performance is primarily attributed to the continuous expansion in overseas markets, coupled with the recovery of the domestic biopharmaceutical industry [1] - The company maintains a strategy of driving performance growth through innovation, supported by sustained high-intensity R&D investments to build core technological barriers [1] - Lean management practices are being implemented to continuously enhance operational efficiency, thereby rapidly improving the company's profitability [1]
港股异动 | 百奥赛图-B(02315)再涨超5% 预计去年归母净利同比增长416.37% 海外市场持续拓展